T/myeloid mixed phenotype acute leukemia
Conditions
Interventions
Experimental Group:Receive one course of treatment with the VHAG regimen
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Before enrollment, the patient must be diagnosed with acute T/ myeloid mixed cell leukemia. The diagnostic criteria refer to the 2022WHO classification. 2. Age >=18 years old and less than 70 years old; 3. The performance status score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0-2 points. 4. Expected survival period >=3 months; 5. During the screening period, there were no organ functional abnormalities that restricted the use of this protocol. 6. Understand the research and sign the informed consent form; 7. Men, women of childbearing age (only postmenopausal women who have been menopausal for at least 12 months or more can be considered infertile) and their partners voluntarily take contraceptive measures deemed effective by the researchers during the treatment period and for at least 12 months after the last use of the study drug.
Exclusion criteria
Exclusion criteria: 1.Patients with known involvement of the central nervous system (CNS) or accompanied by extramedullary lesions; 2. A history of myocardial infarction within 12 months, or clinical manifestations of heart diseases (including but not limited to unstable angina pectoris, congestive heart failure, uncontrolled hypertension and uncontrolled arrhythmia, etc.); Cardiac ultrasound LVEF 1.5 ULN (normal upper limit); ALT or AST > 2.5 ULN; Serum creatinine > 1.5 ULN; Triglyceride > 3 ULN; 6. Known HIV infection; 7. After assessment by the researcher, there are situations that affect the use of the investigational drug; 8. Inability to understand or comply with the research plan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Event free survival;Minimal residual lesion;Relapse free survival;Adverse event; | — |
Countries
China
Contacts
Public ContactJin Jie
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed